Tweedy, Browne Co’s Ionis Pharmaceuticals IONS Stock Holding History

Tweedy, Browne Co’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$171M	Sell	2,275,625 -189,305	-8%	-$14.9M	13.57%	2
2025 Q4	$195M	Sell	2,464,930 -436,286	-15%	-$32.9M	15.74%	1
2025 Q3	$190M	Buy	2,901,216 +9,268	+0.3%	+$452K	16.48%	1
2025 Q2	$114M	Sell	2,891,948 -91,570	-3%	-$3M	10.6%	3
2025 Q1	$90M	Sell	2,983,518 -265,345	-8%	-$8.69M	7.98%	5
2024 Q4	$114M	Sell	3,248,863 -205,813	-6%	-$7.69M	7.66%	6
2024 Q3	$138M	Hold	3,454,676	–	–	6.6%	6
2024 Q2	$165M	Hold	3,454,676	–	–	7.57%	5
2024 Q1	$150M	Hold	3,454,676	–	–	7.03%	5
2023 Q4	$175M	Sell	3,454,676 -55,497	-2%	-$2.66M	8.53%	5
2023 Q3	$159M	Sell	3,510,173 -30,685	-0.9%	-$1.27M	8.52%	4
2023 Q2	$145M	Sell	3,540,858 -188	-0%	-$7.22K	7.63%	5
2023 Q1	$127M	Sell	3,541,046 -90	-0%	-$3.38K	6.89%	6
2022 Q4	$134M	Buy	3,541,136 +818,148	+30%	+$34.4M	7.12%	4
2022 Q3	$120M	Sell	2,722,988 -3,790	-0.1%	-$160K	5.3%	7
2022 Q2	$101M	Sell	2,726,778 -198,324	-7%	-$7.48M	4.13%	8
2022 Q1	$108M	Buy	+2,925,102	New	+$95.7M	3.5%	8

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tweedy, Browne Co's IONS Position: Q1 2026 in Review

Tweedy, Browne Co reduced its Ionis Pharmaceuticals (IONS) stake by 7.7% in Q1 2026, selling an estimated $14.9M and leaving 2,275,625 shares worth $171M. The position accounts for 13.57% of the portfolio, ranked #2.

Tweedy, Browne Co first reported a position in IONS in Q1 2022 and has held it in 17 quarters since. The position peaked at $195M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Tweedy, Browne Co held 2,275,625 shares of Ionis Pharmaceuticals worth $171M as of Q1 2026.
Tweedy, Browne Co sold 189,305 Ionis Pharmaceuticals shares in Q1 2026, an estimated $14.9M.
Ionis Pharmaceuticals made up 13.57% of Tweedy, Browne Co's portfolio in Q1 2026, its #2 holding.
Tweedy, Browne Co first reported a position in Ionis Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
Tweedy, Browne Co's Ionis Pharmaceuticals position peaked at $195M in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Tweedy, Browne Co's 13F filing for Q1 2026, filed 6 May 2026.